Dicerna Pharmaceuticals (DRNA) Shares Up -3.1%

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) shot up 3.1% during trading on Thursday . The company traded as high as $10.98 and last traded at $10.64. 293,553 shares were traded during mid-day trading, a decline of 34% from the average session volume of 442,505 shares. The stock had previously closed at $10.98.

A number of research firms have recently commented on DRNA. Stifel Nicolaus boosted their price objective on Dicerna Pharmaceuticals from $10.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, March 9th. Chardan Capital began coverage on Dicerna Pharmaceuticals in a research report on Friday, March 9th. They issued a “neutral” rating for the company. BidaskClub upgraded Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 28th. HC Wainwright cut Dicerna Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $12.00 price objective for the company. in a research report on Friday, March 23rd. Finally, ValuEngine upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $12.04.

The stock has a market capitalization of $568.40, a P/E ratio of -2.91 and a beta of 2.34.



Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.25). Dicerna Pharmaceuticals had a negative return on equity of 171.81% and a negative net margin of 2,637.15%. The firm had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $1.45 million. The company’s revenue for the quarter was up 976.9% compared to the same quarter last year. analysts anticipate that Dicerna Pharmaceuticals will post -1.15 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Northern Trust Corp increased its position in shares of Dicerna Pharmaceuticals by 6.1% during the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 2,094 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Dicerna Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 14,517 shares in the last quarter. Endurant Capital Management LP purchased a new stake in shares of Dicerna Pharmaceuticals during the fourth quarter worth approximately $170,000. Emerald Advisers Inc. PA purchased a new stake in shares of Dicerna Pharmaceuticals during the fourth quarter worth approximately $266,000. Finally, Millennium Management LLC increased its position in shares of Dicerna Pharmaceuticals by 142.8% during the fourth quarter. Millennium Management LLC now owns 66,907 shares of the biopharmaceutical company’s stock worth $604,000 after purchasing an additional 39,348 shares in the last quarter. Hedge funds and other institutional investors own 75.28% of the company’s stock.

WARNING: This article was first posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://dakotafinancialnews.com/2018/04/14/dicerna-pharmaceuticals-drna-shares-up-3-1.html.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company's preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply